非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C44H58N8O5S |
InChIKeyFVICRBSEYSHKFY-UHFFFAOYSA-N |
CAS号2765081-21-6 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
非小细胞肺癌 | 临床3期 | - | 2025-05-30 | |
转移性胰腺导管腺癌 | 临床3期 | 美国 | 2024-10-16 | |
转移性胰腺导管腺癌 | 临床3期 | 意大利 | 2024-10-16 | |
转移性胰腺导管腺癌 | 临床3期 | 波多黎各 | 2024-10-16 | |
大肠腺癌 | 临床2期 | 美国 | 2024-05-24 | |
转移性结直肠癌 | 临床2期 | 美国 | 2024-05-24 | |
RAS突变非小细胞肺癌 | 临床2期 | 美国 | 2024-01-18 | |
RAS突变非小细胞肺癌 | 临床2期 | 法国 | 2024-01-18 | |
RAS突变非小细胞肺癌 | 临床2期 | 德国 | 2024-01-18 | |
RAS突变非小细胞肺癌 | 临床2期 | 意大利 | 2024-01-18 |
临床1期 | RAS突变非小细胞肺癌 RAS mutant | 73 | 壓齋衊製簾醖選簾繭餘(遞鬱構鑰蓋簾獵憲簾願) = 鑰膚襯構獵範製築鹹遞 觸觸醖觸襯築糧製醖鬱 (繭夢選觸選壓窪網鏇蓋 ) 更多 | 积极 | 2025-03-27 | ||
临床1期 | 74 | 積廠夢遞蓋糧選顧網築(範夢觸蓋艱網構艱願壓) = 遞鑰憲夢衊網夢壓窪壓 簾齋齋鑰窪網糧構齋積 (壓鬱糧糧壓齋築艱壓鏇 ) 更多 | 积极 | 2024-12-02 | |||
積廠夢遞蓋糧選顧網築(範夢觸蓋艱網構艱願壓) = 範糧窪鑰積鬱遞襯憲鏇 簾齋齋鑰窪網糧構齋積 (壓鬱糧糧壓齋築艱壓鏇 ) 更多 | |||||||
临床1期 | 436 | (KRAS G12X + PDAC) | 範鬱獵顧製醖簾顧艱餘(夢築構願鑰鏇選繭糧襯) = 鏇淵廠齋鹹顧願願壓醖 鹹製衊鬱積衊醖廠餘襯 (夢醖網醖齋顧膚觸醖齋, 8.5 ~ NE) 更多 | 积极 | 2024-12-02 | ||
RMC-6236 monotherapy (RAS mutation + PDAC) | 範鬱獵顧製醖簾顧艱餘(夢築構願鑰鏇選繭糧襯) = 積窪齋觸憲顧糧繭衊鑰 鹹製衊鬱積衊醖廠餘襯 (夢醖網醖齋顧膚觸醖齋, 5.9 ~ NE) 更多 | ||||||
临床1期 | 20 | 艱鏇積蓋襯衊遞憲顧膚(範窪憲構壓廠構築夢廠) = 醖積網鏇繭範膚膚鏇築 鹹齋廠選製淵蓋鏇鏇繭 (獵觸餘顧簾鹽範積衊顧 ) | 积极 | 2024-12-02 | |||
临床1期 | 127 | (harboring a KRAS G12X mutation in the second-line (2L) setting) | 憲齋襯顧製廠膚憲選獵(餘憲選繭廠鹽鏇糧積積) = The most common TRAEs were rash and GI-related toxicities that were primarily Grade 1 or 2 in severity. The most common reported Grade ≥3 TRAEs were rash (8%), stomatitis (3%), and diarrhea (2%). 夢糧簾鬱鹹齋網簾壓艱 (餘糧觸衊艱鹹醖鑰壓遞 ) | 积极 | 2024-10-23 | ||
(harboring any RAS mutation in the 2L setting) | |||||||
临床1期 | 肺癌 RRAS | RRAS2 | - | (RRAS Q87L mutation) | 願觸衊壓觸鹹選蓋遞淵(鏇鏇獵憲獵膚窪壓餘壓) = Enhanced ERK phosphorylation was only observed in HBEC-RRASQ87L cells 壓觸淵夢艱齋廠鹹夢顧 (窪鑰憲鹹選餘膚鏇夢糧 ) | 积极 | 2024-09-09 | |
(RRAS2 Q72L mutation) | |||||||
临床1期 | 胰腺导管癌 KRAS G12X | 127 | 淵淵築齋鹽淵膚醖積鏇(築艱蓋築築鏇願築遞顧) = 顧衊鏇構淵蓋鏇醖廠衊 膚顧蓋窪鹹鏇淵憲齋築 (衊廠壓醖醖鹽繭網範膚 ) 更多 | 积极 | 2024-07-15 | ||
临床1期 | 33 | (KRASG12X PDAC) | 糧選願衊窪鹹夢繭醖壓(繭糧積願製艱鹹願襯積) = occurring in ≥10% of patients were rash (52%), diarrhea (21%), nausea (21%), and vomiting (15%) 範網顧鏇淵鏇憲糧廠鹹 (積衊衊蓋簾膚積蓋醖築 ) 更多 | 积极 | 2023-10-22 | ||
(KRASG12X NSCLC) |